Table 3 Treatment exposure in patients treated to disease progression, adverse events in the absence of disease progression, and the overall treated population

Treatment duration, median, months

5.3

3.6

2.9

2.3

3.9

2.8

nab-P dose intensity, median, mg/m²/week

77.8

—

61.2

—

74.1

—

Gem dose intensity, median, mg/m²/week

626.3

695.9

523.4^a

590.9

597.3

674.9

nab-P cumulative dose, median, mg/m²

1738

—

925

—

1425

—

Gem cumulative dose,

median, mg/m²

13,000

10,000

8000^a

7500

11,400

9000

nab-P doses given at 125 mg/m², %

72

—

62

—

71

—

Gem doses given at 1000 mg/m², %

65

75

53

81

63

79

Patients with ≥ 1 nab-P dose reduction, n (%)

103 (46)

—

37 (38)

—

172 (41)

—

Patients with ≥ 1 Gem dose reduction, n (%)

114 (51)

89 (38)

48 (49)

19 (33)

198 (47)

132 (33)

Patients with ≥ 1 nab-P dose delay, n (%)

165 (74)

—

72 (73)

—

300 (71)

—

Patients with ≥ 1 Gem dose delay, n (%)

158 (71)

145 (62)

72 (73)

36 (62)

295 (70)

230 (57)